The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
39
No.
21
May 24, 2013
- Translucent Walls, Modern Classics Create “Corporate Feel” In Office Suite Occupied By Wife of MD Anderson President DePinho
- Guest Editorial: Guideline Promises to End Twenty-Year War Over Mass Screening for Prostate Cancer
- UNM Cancer Center Appoints Four Leaders
- American Cancer Society Awards its Medal of Honor
CCL
Vol.
36
No.
5
May 31, 2013
- Yervoy-Nivolumab Combination Treatment Shrinks Tumors 80 Percent in Three Months
- Single-Agent Phase III Trial Comparing Vectibix to Erbitux Meets Primary Endpoint
- Trial Shows Standard-Dose Radiotherapy Safer, More Effective than Higher Doses
- Vaccine Increases PFS 146%, OS 60% In Phase II Clinical Trial
- Cediranib Demonstates Control In Alveolar Soft Part Sarcoma
- Antibody Targeting PD-L1 Shows Fast Tumor Shrinkage
- Shared Decisionmaking Called For In PSA Screening For Ages 55-69
- ACCP Publishes Guidelines Recommending Low-Dose CT
- Study: Routine CT Not Needed In Detecting DLBCL Remissions
- Surveillance Following Surgery Sufficient in Stage I Seminoma
- Fitness Reduces Risk of Death From Lung, Colorectal, Prostate Cancer in Middle-Aged Men
- NCI CTEP Approved Trials For the Month of May
- FDA Approves Bayer’s Xofigo For Late-Stage Prostate Cancer
TCL
Vol.
39
No.
23
June 07, 2013
TCL
Vol.
39
No.
24
June 14, 2013
- Advocacy Group Urges FDA to Sift Through Avastin Glioblastoma Data—Agency Accepts
- Guest Editorial: Myriad Ruling Becomes a Textbook Case Of How Not To Manage a Patent Portfolio, by Robert Cook-Deegan
- Patenting the Gene: Cancer Advocates and Industry Diverge on Myriad Ruling
- FASEB: Focus on Research Funding, Not PR
- MD Anderson Researcher Charged With Placing Ethylene Glycol In Colleague’s Coffee
TCL
Vol.
39
No.
25
June 21, 2013
- Supreme Court Decision Means FTC Scrutiny As Costly Oncology Drugs Go Off-Patent
- New Jersey Center To Have Two Alliances: One With CINJ—and One With MD Anderson
- Senate Commitee Approves $1.058 Trillion To Reverse Sequestration Cuts
- In Brief: Judith Salerno Named President and CEO of Komen
- Obituaries: Keith Amos, Trudy Small, and Kie Kian Ang
TCL
Vol.
39
No.
26
June 26, 2013
- As Sequestration Hits: Varmus on Living in “Pretty Awful Times”
- UK’s NICE Set to Deny Payments For Zaltrap In Second-Line Metastatic Colorectal Cancer
- Clinical Practice Guidelines Don’t Meet IOM Standards
- USPSTF Recommends Hepatitis C Screening For Baby Boomers
- Northwestern’s Warren Kibbe Named Director of NCI CBIIT
- Obituary: Michael Potter, 89, NIH Researcher
CCL
Vol.
36
No.
6
June 28, 2013
- Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
- Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
- Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
- Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
- Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
- Afinitor Extends PFS In Women With EGFR-2 Positive Disease
- Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
- Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
- CTEP-Approved Trials For the Month of June
- FDA Approves Two Oral Drugs For Metastatic Melanoma
